TrialJournal of hematology & oncology2020

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.

Wei Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.